Catalyst Pharmaceuticals (CPRX) Key Ratios
$31.49
$0.00 (0.00%)As on 21-Jul-2026 09:30EDT
Market cap
$3,855 Mln
Revenue (TTM)
$597 Mln
P/E Ratio
18.2
P/B Ratio
3.8
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -2.11 | 5.63 | 11.65 | 32.52 | 37.80 |
| EBIT | 17.15 | 18.16 | 14.70 | 34.53 | 48.97 |
| Net Profit | 20.94 | 12.33 | 12.15 | 30.58 | 25.10 |
| EPS | 21.28 | 12.38 | 11.05 | 25.29 | 20.70 |
| Book Value | -- | -- | 30.14 | 41.51 | 36.16 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| 38.62 | 40.12 | 49.66 | 48.14 | 43.98 |
| Net Margin
| -- | 33.12 | 37.08 | -- | -- |
| Return on equity
| 25.21 | 25.87 | 22.90 | 25.49 | 29.38 |
| Return on Capital
| 25.04 | 25.62 | -- | 25.40 | 29.21 |
| Return on Assets
| 21.19 | 21.80 | 19.24 | 21.89 | 24.80 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.00 | 0.00 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
--
|
25.40
|
29.21
|
20.53
|
32.24
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
22.90
Higher than Peers by 3.93
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
22.90
|
25.49
|
29.38
|
20.75
|
32.76
|
|
Peer Median
|
18.97
|
--
|
--
|
--
|
--
|
ROA
19.24
Higher than Peers by 16.38
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
19.24
|
21.89
|
24.80
|
16.89
|
27.09
|
|
Peer Median
|
2.86
|
--
|
--
|
--
|
--
|
EBIT Margin
49.66
Higher than Peers by 33.84
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
49.66
|
48.14
|
43.98
|
23.73
|
47.54
|
|
Peer Median
|
15.82
|
--
|
--
|
--
|
--
|
Net Margin
37.08
Higher than Peers by 28.84
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
37.08
|
36.39
|
33.33
|
17.93
|
38.27
|
|
Peer Median
|
8.23
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
11.65
Higher than Peers by 3.60
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
11.65
|
0.20
|
0.23
|
0.86
|
0.52
|
|
Peer Median
|
8.05
|
--
|
--
|
--
|
--
|
EBIT Growth
14.70
Higher than Peers by 6.44
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
14.70
|
31.10
|
128.82
|
-7.19
|
94.40
|
|
Peer Median
|
8.26
|
--
|
--
|
--
|
--
|
Net Profit Growth
12.15
Higher than Peers by 4.42
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
12.15
|
30.78
|
129.50
|
-14.05
|
110.42
|
|
Peer Median
|
7.73
|
--
|
--
|
--
|
--
|
EPS Growth
11.05
Higher than Peers by 0.66
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
11.05
|
0.30
|
1.07
|
-0.14
|
1.02
|
|
Peer Median
|
10.39
|
--
|
--
|
--
|
--
|
Book Value Growth
27.55
Higher than Peers by 22.68
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
27.55
|
--
|
--
|
--
|
--
|
|
Peer Median
|
4.87
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
--
|
0.00
|
0.00
|
0.01
|
0.01
|
|
Peer Median
|
0.59
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.00
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
7.10
Higher than Peers by 5.45
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
7.10
|
6.08
|
5.17
|
2.88
|
5.57
|
|
Peer Median
|
1.65
|
--
|
--
|
--
|
--
|
Quick Ratio
6.84
Higher than Peers by 5.64
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
6.84
|
5.82
|
5.01
|
2.68
|
5.45
|
|
Peer Median
|
1.20
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
--
|
--
|
--
|
--
|
24.72
|
|
Peer Median
|
4.77
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
22.00
Higher than Peers by 0.72
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
22.00
|
21.78
|
13.32
|
13.44
|
5.04
|
|
Peer Median
|
21.27
|
--
|
--
|
--
|
--
|
Asset Turnover
0.52
Higher than Peers by 0.12
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
0.52
|
0.60
|
0.74
|
0.94
|
0.70
|
|
Peer Median
|
0.40
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
--
|
60.08
|
44.20
|
29.49
|
14.93
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
--
|
118.69
|
93.34
|
78.89
|
77.92
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
--
|
58.18
|
83.26
|
65.96
|
35.80
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
--
|
120.59
|
54.27
|
42.42
|
57.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
18.20
Lower than Peers by 19.12
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
18.20
|
13.86
|
16.08
|
26.78
|
25.42
|
|
Peer Median
|
37.32
|
--
|
--
|
--
|
--
|
Price / Book Value
3.81
Lower than Peers by 3.95
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
3.81
|
3.11
|
3.62
|
4.93
|
7.03
|
|
Peer Median
|
7.75
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.50
|
--
|
--
|
--
|
--
|
EV/EBITDA
10.14
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
10.14
|
7.04
|
8.35
|
13.96
|
17.63
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
3,855
Higher than Peers by 1,334
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
3,855
|
--
|
--
|
--
|
--
|
|
Peer Median
|
2,521
|
--
|
--
|
--
|
--
|